AR226-2531 TO: B.

AR226-2643 SHI AR226-2643 --92SS0''' PROJECT 1200000GW SAMPLING 8/02 GW SAMPLING 8/02 GW SAMPLING 8/02 GW SAMPLING 8/02 202000GW SAMPLING 8/02 GW SAMPLING 8/02 201000GW SAMPLING 8/02 GW SAMPLING 8/02 212000GW SAMPLING 8/02 GW SAMPLING 8/02 SRCNAME THEME DATESMPL SMPLT WELL1 Groundwater 8/6/2002 FS WELL10 Groundwater 8/6/2002 FS WELL2 Groundwater 8/6/2002 FS WELL3 Groundwater 8/6/2002 FS WELL4 Groundwater 8/6/2002 FS WELL5 Groundwater 8/6/2002 FS WELL6 Groundwater 8/6/2002 FS WELL7 Groundwater 8/6/2002 FS WELL8 Groundwater 8/6/2002 FS WELL9 Groundwater 8/6/2002 FS SAMPLE_NUMBER SH-WELL1 SH-WELL10 SH-WELL2 SH-WELL3 SH-WELL4 SH-WELL5 SH-WELL6 SH-WELL7 SH-WELL8 SH-WELL9 TOP BOTTOM FILTERED T T T T T T T T T T CASNO 3825261 3825261 3825261 3825261 3825261 3825261 3825261 3825261 3825261 3825261 ANALYTE FC-143 FC-143 FC-143 FC-143 FC-143 FC-143 FC-143 FC-143 FC-143 FC-143 RsItPost 306000 698000 697000 31700 243000 1540000 RsItVal UNITS 1200000 NG/L 306000 NG/L 698000 NG/L 697000 NG/L 202000 NG/L 31700 NG/L 201000 NG/L 243000 NG/L 212000 NG/L 1540000 NG/L Hit LAB_ANALYTE 1 FC-143 1 FC-143 1 FC-143 1 FC-143 1 FC-143 1 FC-143 1 FC-143 1 FC-143 1 FC-143 1 FC-143 QUAL EPA QUALJNHOUSE REVIEW METHODNO 01M-008-046 01M-008-046 01M-008-046 01 M-008-046 01 M-008-046 01 M-008-046 01 M-008-046 01 M-008-046 01M-008-046 01 M-008-046 AR226-2643 C8 results Envista 111104.xls Page 1 PREPMTHD PREPREP DRY LAB NUMBER RSLTMOD RESULT UNIT MDL PQL DUPNO None NS 1 L33570-1 1200000 NG/L 500000 1 None NS 1 L33570-10 306000 NG/L 50000 1 None NS 1 L33570-2 698000 NG/L 500000 1 None NS 1 L33570-3 697000 NG/L 500000 1 None NS 1 L33570-4 202000 NG/L 50000 1 None NS 1 L33570-5 31700 NG/L 5000 1 None NS 1 L33570-6 201000 NG/L 50000 1 None NS 1 L33570-7 243000 NG/L 500000 1 None NS 1 L33570-8 212000 NG/L 50000 1 None NS 1 L33570-9 1540000 NG/L 500000 1 SHI C8 results Envista 111104.xls Page 2

r 3 SfM Ammonium Perfluorooctanoate: Cross-Sectional Surveillance in a Community Sample of Clinical Measures of General Health Status Related to a Serum Biomarker of Exposure A Study Protocol Preparedfo r DuPont Haskell Laboratory Newark, Delaware Prepared by The Sapphire Group, Inc.

AR226-2841 vy Copies toil Haskell L a b !

This study ss Standard (40 CFK 7#, study records.

AR226-3035 DuPont HUI 822-95 HASKELL LABORATORY POR TOXICOLOGY AUD INDUSTRIAL MEDICINE STATIC, ACUTE 48-HOOK SCREENING TEST OF H-21460 Daphnie w a a , CONTINUED Based on visual observations, all solutions were clear, except for 50 mg/L which was slightly cloudy, 500 mg/L which was cloudy, and 5000 mg/L which was cloudy and white in color.

AR226-3122 g a ttm ia * u v 5 a c E W j :i3 ^ g iw v s a ^ mr7BTn;p,'iiaBgT.gncnCTO T fa a y ^ j: CONFIDENTIAL DPT 429/984523/AC ACUTE ORAL TO XICITY TO THE RAT (FIXED DOSE M ETH O D) Sponsor DuPont Speciality Chemicals Jackson Laboratory Chambers Works Deepwater NJ 08023 USA Research Laboratory Huntingdon Life Sciences Ltd P.O.

M a t - 2/?

\ o \ 00 " sn y itt TRADE SECRET Study Title H-24743: Biopersistence Screening 10-Dose Oral Gavage Study in Rats Laboratory Project ID : DuPont-1155 8 DuPont-11558 Author: Carol Finlay, B.A.

AfUAG- 3lf7 / 0 a*K 000152 ftW 6 - RESEARCH i Prets Research.

AlU siel 36U ADVANCE UNEDITED DRAFT DRAFT RISK PROFILE OUTLINE EXECUTIVE SUMMARY 1 1NTRODUCTION 1.1 Chemical Identity of the proposed substance Mention who has made the proposal and when Spell out the specific chemical identity and particular considerations related to that 1.2 Conclusion of the POP Review Committee of Annex D information "POP RC has evaluated Annex D (add reference to the meeting and the decision) information and has concluded that ..." 1.3 Data sources short overview of the data sources provided by the proposing Party and/or used by the POP RC in Annex D screening short overview of data submitted by Parties and observers (NB: a more elaborated summary of the submissions may be provided as a separate POP RC INF document) information on availability of national and international assessment reports; [1.4 Summary of available risk information brief summary of the submitted evaluations and other information referred to in Annex E, point f ' Alternatively, can be summarised in a separate POP RC INF document ] 1.5 Status of the chemical under international conventions 2 SUMMARY INFORMATION RELEVANT FOR THE RISK PROFILE 2.1 Sources production, trade, stockpiles uses releases to the environment 2.2 Environmental fate Further elaboration of information referred to in Annex D, paragraphs (b) - (d); based on all relevant available information ' Monitoring data available integrated under the subheading or alternatively dealt with under separate heading "Monitoring data" Could be split in: 2.2.1 Persistence 2.2.2 Bioaccumulation 2.2.3 Long range environmental transport 000222 P-2 2.3 Exposure Summary of relevant information concerning exposure in local areas (both near the source and in remote areas) Summary of relevant information concerning exposure as a result of LRET Information on bioavailability 2.4 Hazard assessment for endpoints of concern Further elaboration of information referred to in Annex D, paragraph (e); based on all relevant available information Monitoring data on effects included 3 SYNTHESIS OF THE INFORMATION synthesis of the information under chapter 2 that focus on information that is leading to the conclusive statement under chapter 4 4 CONCLUDING STATEMENT Is the chemical likely, as a result of LRET, to lead to significant adverse human health and/or environmental effects, such that global action is warranted Note: No Annexes; all other data provided as POP RC INF documents Target size not longer than 20 pages 2 000223

A f . 2 . i > 6 f c/ exhibit a P-2 Weekly Morbidity and Mortality Weekly Report ___________May 5, 2006 /Vol. 55 / No. 17 State Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation -- United States, 2003 Arthritis is costly ($86 billion annually), highly prevalent (affecting 43 million U.S. adults), the leading cause of dis ability, and associated with substantial disparities in pain, activity limitations, and compromised quality of life (1- 3).

M - 37,0 C; -- WASHINGTON WORKS C-8 INDUSTRIAL HYGIENE A.

-f\ R o iQ _ o s rs ~ PFOS Pharmacokinetic - 7 000223 C O V iH tfc I ^ the development services company Covane Laboratories Inc.

AR N-Et FOSE alcohol IAcute Toxicity - 0002S8 International Research and Development Corporation SPONSOR: TEST MATERIAL: SUBJECT: 3M Company FM-3422 Acute Oral Toxicity (LD,n) Study in Rats.